Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Martín Martorell

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
The Netherlands Journal of Medicine|November 15, 2002
Autoimmunity in Addison's diseaseP Martín Martorell, B O Roep, J W A Smit, et al.
ESMO Open|April 22, 2021
In the literature: April 2021P Martín-Martorell, I Gonzalez-Barrallo, V Gambardella, et al.
British Journal of Cancer|July 31, 2008
Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution trialP Martín-Martorell, S Roselló, E Rodríguez-Braun, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|December 7, 2007
Nonbacterial thrombotic endocarditis associated with lung adenocarcinomaP Martín-Martorell, A Insa-Molla, M I Chirivella-González, et al.
The Netherlands Journal of Medicine|March 18, 2011
Long-term follow-up of organ-specific antibodies and related organ dysfunction in type 1 diabetes mellitusL C G de Graaff, P Martín-Martorell, J Baan, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|April 30, 2014
Subcutaneous trastuzumab: drug development and current positionP Martín Martorell, B Bermejo de Las Heras, J A Pérez-Fidalgo, et al.
ESMO Real World Data and Digital Oncology|July 1, 2026
First-line osimertinib in advanced <i>EGFR</i>-mutated NSCLC: real-world outcomes, clinicogenomic correlates, and oligoprogression management in a multicenter Spanish cohortG Suay, S Cases-Esteban, P Capdevila, et al.
ESMO Open|October 25, 2025
COMPEL: osimertinib plus platinum-based chemotherapy in patients with EGFR-mutated advanced NSCLC and progression on first-line osimertinibN Peled, A Tufman, L V Sequist, et al.
ESMO Open|September 25, 2025
Enhancing precision oncology: the role of molecular tumor boards in early identification and targeted treatment of ESCAT II-III alterationsV Seguí, J A Carbonell-Asins, J Martín-Arana, et al.
Cancer Letters|September 11, 2025
NNMT-driven metabolic reprogramming creates a NAMPT druggable vulnerability and reveals liquid biopsy biomarkers for TKI resistance in EGFR-mutant NSCLCI Pulido, J C García-Cañaveras, M L Rodríguez, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
The Netherlands Journal of Medicine|November 15, 2002
Autoimmunity in Addison's diseaseP Martín Martorell, B O Roep, J W A Smit, et al.
ESMO Open|April 22, 2021
In the literature: April 2021P Martín-Martorell, I Gonzalez-Barrallo, V Gambardella, et al.
British Journal of Cancer|July 31, 2008
Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution trialP Martín-Martorell, S Roselló, E Rodríguez-Braun, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|December 7, 2007
Nonbacterial thrombotic endocarditis associated with lung adenocarcinomaP Martín-Martorell, A Insa-Molla, M I Chirivella-González, et al.
The Netherlands Journal of Medicine|March 18, 2011
Long-term follow-up of organ-specific antibodies and related organ dysfunction in type 1 diabetes mellitusL C G de Graaff, P Martín-Martorell, J Baan, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|April 30, 2014
Subcutaneous trastuzumab: drug development and current positionP Martín Martorell, B Bermejo de Las Heras, J A Pérez-Fidalgo, et al.
ESMO Real World Data and Digital Oncology|July 1, 2026
First-line osimertinib in advanced <i>EGFR</i>-mutated NSCLC: real-world outcomes, clinicogenomic correlates, and oligoprogression management in a multicenter Spanish cohortG Suay, S Cases-Esteban, P Capdevila, et al.
ESMO Open|October 25, 2025
COMPEL: osimertinib plus platinum-based chemotherapy in patients with EGFR-mutated advanced NSCLC and progression on first-line osimertinibN Peled, A Tufman, L V Sequist, et al.
ESMO Open|September 25, 2025
Enhancing precision oncology: the role of molecular tumor boards in early identification and targeted treatment of ESCAT II-III alterationsV Seguí, J A Carbonell-Asins, J Martín-Arana, et al.
Cancer Letters|September 11, 2025
NNMT-driven metabolic reprogramming creates a NAMPT druggable vulnerability and reveals liquid biopsy biomarkers for TKI resistance in EGFR-mutant NSCLCI Pulido, J C García-Cañaveras, M L Rodríguez, et al.
Pageof 1